Key Highlights
- XCUR is trading up 21.29% at $1.23 on October 22, with a market capitalization of about $8.1 million, calculated.
- The prior close was $1.01, and the shares were indicated higher before the open.
- Nasdaq extended the stockholders' equity deadline to December 2, 2026, against a $2.5 million minimum.
- Reported stockholders' equity was about $2.1 million at March 31, 2026.
- Cash was $3.7 million at the end of 2025, down from $12.5 million a year earlier.
Why Is Exicure Penny Stock Surging on October 22?
Exicure (NASDAQ:XCUR) is trading up 21.29% at $1.23 on October 22, and no company announcement was identified for the session. The prior close was $1.01, and the shares were already indicated about 10% higher before the open.
What investors may be missing is the compliance clock behind the penny stock. The latest company release was a September 16 notice that Nasdaq had extended the deadline to regain a $2.5 million minimum stockholders' equity to December 2, 2026. With roughly 6.55 million shares outstanding, the market capitalization at $1.23 is about $8.1 million, calculated.
How Serious Is the Nasdaq Equity Deadline?
Nasdaq notified the company on June 5 that reported stockholders' equity of about $2.1 million at March 31 was below the requirement, and it was granted up to 180 days to regain compliance after submitting a plan. The company also does not meet Nasdaq's alternative standards, so missing the December 2 date could lead to a delisting determination, which it could appeal.
A separate delinquency notice on May 28 over a late first-quarter Form 10-Q was resolved when the company filed on May 29. Two compliance matters in a single year show how closely the company is monitored. With the deadline roughly six weeks away, calculated from today's date, the equity gap is the central issue for shareholders.
What Do the Cash Figures and Share Issuance Say?
For 2025 the company reported a net loss of $4.9 million and year-end cash of $3.7 million, down from $12.5 million a year earlier. Management said then that current liquidity might not cover operations for the next 12 months.
On August 3 the company said it would issue 172,058 shares to GPCR Therapeutics, valued at about $1.0 million at $5.81 per share, to settle a clinical milestone tied to the Phase 2 burixafor trial. That issuance used equity instead of cash, which preserves liquidity but adds to the share count.
On June 30 a director resigned, and two new Class III directors joined, expanding the board from five to six members.
What Is Burixafor, and What Comes Next?
Exicure is a clinical-stage biotechnology company developing burixafor (GPC-100), a candidate being studied in blood disorders and cancers. On April 22 it announced a co-development agreement with Adbiotech to explore burixafor combinations in sickle cell disease, acute myeloid leukemia and solid tumors. Adbiotech is listed in South Korea, and the agreement is aimed at exploring combination therapies.
The December 2 Nasdaq deadline is the clearest date ahead. Investors will watch for any capital raise, equity-restoring transaction or clinical update, since none was identified for today's session. The Adbiotech agreement, the GPCR milestone settlement and the board changes are the other items on record this year, and none is dated within the past month, so the session has no company-specific explanation.






Please wait processing your request...